Top

Published in:

Open Access 01-12-2021 | Cytostatic Therapy | Research article

Molecular response to induction chemotherapy and its correlation with treatment outcome in head and neck cancer patients by means of NMR-based metabolomics

Authors: Łukasz Boguszewicz, Agata Bieleń, Jarosław Dawid Jarczewski, Mateusz Ciszek, Agnieszka Skorupa, Krzysztof Składowski, Maria Sokół

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The aim of this prospective study is to identify the biomarkers associated with the effects of induction chemotherapy (iCHT) in terms of the favorable/weaker response to the treatment in locally advanced head and neck squamous cells carcinomas (LA-HNSCC).

Methods

The studied group consisted of 53 LA-HNSCC patients treated with iCHT. The treatment tolerance was measured by the Common Terminology Criteria for Adverse Events (CTCAE). The response to the treatment was evaluated by the clinical, fiberoptic and radiological examinations made before and after iCHT (the TNM Classification of Malignant Tumors was used for classifying the extent of cancer spread). Proton nuclear magnetic resonance (¹H NMR) serum spectra of the samples collected before and after iCHT were acquired with a 400 MHz spectrometer and analyzed using the multivariate and univariate statistical methods.

Results

The molecular response to iCHT involves an increase of the serum lipids which is accompanied by the simultaneous decrease of alanine, glucose and N-acetyl-glycoprotein (NAG). Furthermore, in males, the iCHT induced changes in the lipid signals and NAG significantly correlate with the regression of the primary tumor. The OPLS-DA multivariate model identified two subgroups of the patients with a weaker metabolic and clinical response. The first one consisted of the patients with a significantly lower initial nodal stage, the second one showed no differences in the initial clinical and metabolic statuses.

Conclusions

The NMR-based metabolomic study of the serum spectra revealed that iCHT induces the marked changes in the LA-HNSCC patients’ metabolic profiles and makes it possible to stratify the patients according to their response to iCHT. These effects are sex dependent. Further studies on a larger scale accounting for sex and the clinical and metabolic factors are warranted.

Available only for authorised users

Fayette J, et al. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.8934.

Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018;29(5):1130–40. https://doi.org/10.1093/annonc/mdy102.CrossRefPubMedPubMedCentral

de Bree R, Wolf GT, de Keizer B, Nixon IJ, Hartl DM, Forastiere AA, et al. Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: from physical examination to modern imaging techniques and beyond. Head Neck. 2017;39(11):2329–49. https://doi.org/10.1002/hed.24883.CrossRefPubMedPubMedCentral

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–15. https://doi.org/10.1056/NEJMoa070956.CrossRefPubMed

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704. https://doi.org/10.1056/NEJMoa071028.CrossRefPubMed

Albers AE, Grabow R, Qian X, Jumah MD, Hofmann VM, Krannich A, et al. Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck. Mol Clin Oncol. 2017;7(1):151–7. https://doi.org/10.3892/mco.2017.1281.CrossRefPubMedPubMedCentral

Rapidis A, Sarlis N, Lefebvre JL, Kies M. Docetaxel in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag. 2008;4(5):865–86. https://doi.org/10.2147/TCRM.S3133.CrossRefPubMedPubMedCentral

Jin T, Qin WF, Jiang F, Jin QF, Wei QC, Jia YS, et al. Cisplatin and fluorouracil induction chemotherapy with or without Docetaxel in Locoregionally advanced nasopharyngeal carcinoma. Transl Oncol. 2019;12(4):633–9. https://doi.org/10.1016/j.tranon.2019.01.002.CrossRefPubMedPubMedCentral

Galizia D, Milani A, Geuna E, Martinello R, Cagnazzo C, Foresto M, et al. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: a prospective study. Cancer Med. 2018;7(9):4339–44. https://doi.org/10.1002/cam4.1687.CrossRefPubMedPubMedCentral

10.

Kim HI, Lim H, Moon A. Sex differences in cancer: epidemiology, genetics and therapy Biomol. Ther. 2018;26(4):335–42.

11.

Wang J, Huang Y. Pharmacogenomics of sex difference in chemotherapeutic toxicity. Curr Drug Discov Technol. 2007;4(1):59–68. https://doi.org/10.2174/157016307781115485.CrossRefPubMed

12.

Masuda M, Toh S, Wakasaki T, Suzui M, Joe AK. Somatic evolution of head and neck cancer—biological robustness and latent vulnerability. Mol Oncol. 2013;7(1):14–28. https://doi.org/10.1016/j.molonc.2012.10.009.CrossRefPubMed

13.

Tribius S, Reemts E, Prosch C, Raguse M, Petersen C, Kruell A, et al. Global quality of life during the acute toxicity phase of multimodality treatment for patients with head and neck cancer: can we identify patients most at risk of profound quality of life decline? Oral Oncol. 2012;48(9):898–904. https://doi.org/10.1016/j.oraloncology.2012.03.011.CrossRefPubMed

14.

Santa Cruz O, Tsoutsou P, Castella C, Khanfir K, Anchisi S, Bouayed S, et al. Locoregional control and toxicity in head and neck carcinoma patients following helical Tomotherapy-delivered intensity-modulated radiation therapy compared with 3D-CRT data. Oncology. 2018;95(2):61–8. https://doi.org/10.1159/000489217.CrossRefPubMed

15.

Hsieh JC-H, et al. Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. Head Neck. 2019;41(S1):19–45. https://doi.org/10.1002/hed.25932.CrossRefPubMed

16.

Miolo G, et al. Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.9489.

17.

Wei S, Liu L, Zhang J, Bowers J, Gowda GAN, Seeger H, et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol. 2013;7(3):297–307. https://doi.org/10.1016/j.molonc.2012.10.003.CrossRefPubMed

18.

Sun Y, Kim JH, Vangipuram K, Hayes DF, Smith EML, Yeomans L, et al. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. 2018;171(3):657–66. https://doi.org/10.1007/s10549-018-4862-3.CrossRefPubMedPubMedCentral

19.

Jobard E, Blanc E, Négrier S, Escudier B, Gravis G, Chevreau C, et al. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. Br J Cancer. 2015;113(8):1148–57. https://doi.org/10.1038/bjc.2015.322.CrossRefPubMedPubMedCentral

20.

Yang K, Zhang F, Han P, Wang ZZ, Deng K, Zhang YY, et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for colorectal cancer. Metabolomics. 2018;14(9):110. https://doi.org/10.1007/s11306-018-1406-0.CrossRefPubMed

21.

Ye G, Liu Y, Yin P, Zeng Z, Huang Q, Kong H, et al. Study of induction chemotherapy efficacy in oral squamous cell carcinoma using pseudotargeted metabolomics. J Proteome Res. 2014;13(4):1994–2004. https://doi.org/10.1021/pr4011298.CrossRefPubMed

22.

Jelonek K, Krzywon A, Jablonska P, Slominska EM, Smolenski RT, Polanska J, et al. Systemic effects of radiotherapy and concurrent chemo-radiotherapy in head and neck Cancer patients—comparison of serum Metabolome profiles. Metabolites. 2020;10(2). https://doi.org/10.3390/metabo10020060.

23.

Taylor S, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol. 1994;12(2):385–95. https://doi.org/10.1200/JCO.1994.12.2.385.CrossRefPubMed

24.

Dunphy FR, Dunleavy TL, Harrison BR, Trinkaus KM, Kim HJ, Stack BC, et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 and 1999. Cancer. 2001;91(5):940–8. https://doi.org/10.1002/1097-0142(20010301)91:5<940::AID-CNCR1083>3.0.CO;2-A.CrossRefPubMed

25.

http://evs.nci.nih.gov/ftp1/CTCAE/About.html Accessed 27 October 2020.

26.

Boguszewicz, Ł., Hajduk A., Mrochem-Kwarciak J., Skorupa A., Ciszek M., Heyda A., Składowski K., Sokół M. 1H NMR based metabolomic approach to monitoring of the head and neck cancer treatment toxicity. Metabolomics. 2016; https://doi.org/https://doi.org/10.1007/s11306-016-1043-4, 12, 6.

27.

Boguszewicz Ł, Bieleń A, Mrochem-Kwarciak J, Skorupa A, Ciszek M, Heyda A, et al. NMR-based metabolomics in real-time monitoring of treatment induced toxicity and cachexia in head and neck cancer: a method for early detection of high risk patients. Metabolomics. 2019;15(8):110. https://doi.org/10.1007/s11306-019-1576-4.CrossRefPubMedPubMedCentral

28.

Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter T, et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis. 2019;10(8):540. https://doi.org/10.1038/s41419-019-1769-9.CrossRefPubMedPubMedCentral

29.

Alexopoulos CG, Pournaras S, Vaslamatzis M, Avgerinos A, Raptis S. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother Pharmacol. 1992;30(5):412–6. https://doi.org/10.1007/BF00689971.CrossRefPubMed

30.

Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN, Dontas IA, Karamanos BG, Karayiannacos PE. Influence of 5-fluorouracil on serum lipids. Acta Oncol. 1995;34(2):253–6. https://doi.org/10.3109/02841869509093964.CrossRefPubMed

31.

Wang Y, et al. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.10145.

32.

Wang G, Su C, Yin T. Paclitaxel and platinum-based chemotherapy results in transient dyslipidemia in cancer patients. Mol Clin Oncol. 2017;6(2):261–5. https://doi.org/10.3892/mco.2016.1107.CrossRefPubMed

33.

Sharma M, Tuaine J, McLaren B, Waters DL, Black K, Jones LM, et al. Chemotherapy agents alter plasma lipids in breast cancer patients and show differential effects on lipid metabolism genes in liver cells. PLoS One. 2016;11(1):e0148049. https://doi.org/10.1371/journal.pone.0148049.CrossRefPubMedPubMedCentral

34.

Tian W, Yao Y, Fan G, Zhou Y, Wu M, Xu D, et al. Changes in lipid profiles during and after (neo)adjuvant chemotherapy in women with early-stage breast cancer: a retrospective study. PLoS One. 2019;14(8). https://doi.org/10.1371/journal.pone.0221866.

35.

Poorey VK, Thakur P. Alteration of lipid profile in patients with head and neck malignancy. Indian J Otolaryngol Head Neck Surg. 2016;68(2):135–40. https://doi.org/10.1007/s12070-015-0829-4.CrossRefPubMed

36.

Soininen P, Kangas AJ, Würtz P, Tukiainen T, Tynkkynen T, Laatikainen R, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst. 2009;134(9):1781. https://doi.org/10.1039/b910205a.CrossRefPubMed

37.

Georges P, Chaussain JL, Gendrel D, Donnadieu M, Job JC. Plasma glucose and alanine relationship after fast in normal children and children with ketotic hypoglycemia. Pediatr Res. 1981;15(1):89. https://doi.org/10.1203/00006450-198101000-00110.CrossRef

38.

Faerch K, Borch-Johnsen K, Vaag A, Jørgensen T, Witte DR. Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. Diabetologia. 2010;53(5):858–65. https://doi.org/10.1007/s00125-010-1673-4.CrossRefPubMed

39.

Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. Physiol Behav. 2018;187:20–3. https://doi.org/10.1016/j.physbeh.2017.08.016.CrossRefPubMed

40.

Tiziani S, Lopes V, Günther UL. Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia. 2009;11(3):269–IN10. https://doi.org/10.1593/neo.81396.CrossRefPubMedPubMedCentral

41.

Banks I. No man's land: men, illness, and the NHS. BMJ. 2001;323(7320):1058–60. https://doi.org/10.1136/bmj.323.7320.1058.CrossRefPubMedPubMedCentral

42.

Hoang T, Zhang C, Geye HM, Speer T, Yu M, Wiederholt PA, et al. Gender associations in head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2017;30(15_suppl):e16010. https://doi.org/10.1200/jco.2012.30.15_suppl.e16010.CrossRef

43.

Torri GM, Torri J, Gulian JM, Vion-Dury J, Viout P, Cozzone PJ. Magnetic resonance spectroscopy of serum and acute-phase proteins revisited: a multiparametric statistical analysis of metabolite variations in inflammatory, infectious and miscellaneous diseases. Clin Chim Acta. 1999;279(1-2):77–96. https://doi.org/10.1016/S0009-8981(98)00166-1.CrossRefPubMed

Title: Molecular response to induction chemotherapy and its correlation with treatment outcome in head and neck cancer patients by means of NMR-based metabolomics
Authors: Łukasz Boguszewicz
Agata Bieleń
Jarosław Dawid Jarczewski
Mateusz Ciszek
Agnieszka Skorupa
Krzysztof Składowski
Maria Sokół
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08137-4

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM)

A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma

Predictive nomogram for postoperative pancreatic fistula following pancreaticoduodenectomy: a retrospective study

Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety

Virtual reality for 3D histology: multi-scale visualization of organs with interactive feature exploration